Clinical trial

Kisspeptin Influence on Glucose Homeostasis

Name
2016P001769
Description
The goal of this study is to learn about how a naturally occurring hormone called kisspeptin affects blood sugar and insulin levels.
Trial arms
Trial start
2017-07-18
Estimated PCD
2024-08-01
Trial end
2024-08-01
Status
Recruiting
Phase
Early phase I
Treatment
kisspeptin 112-121
Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
Arms:
Kisspeptin and Insulin Resistance Test
Other names:
metastin 45-54
Insulin Resistance Test
Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
Arms:
Kisspeptin and Insulin Resistance Test, Placebo and Insulin Resistance Test
Placebo
Receive IV fluids for up to 16 hours that do not contain any study drug
Arms:
Placebo and Insulin Resistance Test
Size
413
Primary endpoint
Average difference in area under the curve of insulin in response to a mixed meal tolerance test
4 hours
Eligibility criteria
Inclusion/Exclusion Criteria: History: * normal pubertal development * stable weight for previous three months * no active illicit drug use, * no history of a medication reaction requiring emergency medical care, * no difficulty with blood draws. Physical examination: • systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg, Laboratory studies: (per MGH reference ranges) * normal hemoglobin, unless hypogonadal then no lower than 0.5 gm/dL below the lower limit of the reference range for normal women (as men and women with hypogonadism have lower hemoglobin levels off of treatment) * hemoglobin A1C \< 6.5% * BUN, creatinine not elevated * AST, ALT \< 3x upper limit of normal * negative serum pregnancy test (for all women) * no hyperlipidemia by fasting lipid panel Additional Criteria by Study Population Healthy Men: * normal body mass index (BMI between 18.5-25) * no history of chronic disease, except well controlled thyroid disease * no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable. * no history of diabetes in a first degree relative. Healthy Women: * normal body mass index (BMI between 18.5-25) * no history of chronic disease, except well controlled thyroid disease, * no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable. * no history of diabetes in a first degree relative, * no use of contraceptive pills, patches or vaginal rings within last 4 weeks. * regular menstrual cycles Postmenopausal Women: * body mass index (BMI between 18.5-30) * no history of chronic disease except thyroid disease, and osteoporosis, * no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine, osteoporosis medications or seasonal allergy medications is acceptable, * no history of diabetes in a first degree relative, * normal activate protein C resistance screen, * if applicable, able to undergo appropriate washout from hormone therapy. Men and Women with Impaired Glucose Tolerance (IGT): * diagnosis of impaired glucose tolerance by oral glucose tolerance test, * all medical conditions well-controlled. Men and Women with Hypogonadism * diagnosis of hypogonadism, * all other medical conditions well-controlled, * if applicable, able to undergo appropriate washout from hormone therapy.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 413, 'type': 'ESTIMATED'}}
Updated at
2023-07-19

1 organization

1 product

2 indications

Product
Kisspeptin
Indication
Hypogonadism